Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCIR.L Regulatory News (CIR)

  • There is currently no data for CIR

Stabilisation Notice

13 Mar 2014 07:01

RNS Number : 2131C
Circassia Pharmaceuticals PLC
13 March 2014
 



NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT OR ANY COPY OF IT

 

CIRCASSIA PHARMACEUTICALS PLC

 

Stabilisation Notice

 

 

13 March 2014

 

J.P. Morgan Securities plc (contact: Manuel Esteve; telephone: +44 (0)20 7742 4000) hereby gives notice that it may stabilise the offer of the following securities in accordance with Commission Regulation (EC) No. 2273/2003 implementing the Market Abuse Directive (2003/6/EC).

 

The securities:

 

Issuer:

 

Circassia Pharmaceuticals plc

Shares:

 

Ordinary Shares of 0.08 pence each (ISIN: GB00BJVD3B28)

 

Offering size:

 

67,419,356 Shares

Offer price:

 

310 pence per Share

Stabilisation:

 

Stabilising Manager:

 

J.P. Morgan Securities plc

Stabilisation period expected to start on:

 

13 March 2014

Stabilisation period expected to end no later than:

 

11 April 2014

Maximum size of over-allotment facility:

 

10,112,903 Shares

Greenshoe Option:

 

Terms:

The Issuer has granted to J.P. Morgan Securities plc, in its capacity as stabilising manager, the option to acquire up to an additional 10,112,903 Shares

 

 

Duration:

This option may be exercised by the Stabilising Manager in whole or in part on one or more occasions at any time from 13 March 2014 to 11 April 2014

 

In connection with the offer of the above securities, the Stabilising Manager may over-allot the securities or effect transactions with a view to supporting, stabilising or maintaining the market price of the securities at a level which might not otherwise prevail in the open market. However, there is no assurance that the Stabilising Manager will take any stabilisation action and any stabilisation action, if begun, may be ended at any time without prior notice.

 

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

 

This announcement is not for publication, distribution or release, in whole or in part, directly or indirectly, in or into the United States of America (including its territories and possessions, any state of the United States of America and the District of Columbia) (the "United States"), Australia, Canada, Japan or any other jurisdiction where distribution would be unlawful. This announcement does not constitute, or form part of, an offer to sell, or a solicitation of an offer to purchase, any securities in the United States, Australia, Canada, Japan or any other jurisdiction where such an offer would be unlawful.

 

The securities of the Issuer have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. The securities referred to herein have not been registered under the applicable securities laws of Australia, Canada or Japan and, subject to certain exceptions, may not be offered or sold within Australia, Canada or Japan or to any national, resident or citizen of Australia, Canada or Japan. The distribution of this announcement in other jurisdictions may be restricted by law and persons into whose possession this announcement comes should inform themselves about, and observe such restrictions.

 

In addition, if and to the extent that this announcement is communicated in, or the offer of the securities to which it relates is made in, any EEA Member State that has implemented Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the "Prospectus Directive") before the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Member State in accordance with the Prospectus Directive (or which has been approved by a competent authority in another Member State and notified to the competent authority in that Member State in accordance with the Prospectus Directive), this announcement and the offer are only addressed to and directed at persons in that Member State who are "qualified investors" within the meaning of the Prospectus Directive (or who are other persons to whom the offer may lawfully be made) and must not be acted on or relied on by other persons in that Member State.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STAJJMFTMBIBMAI
Date   Source Headline
8th Jul 20195:02 pmRNSHolding(s) in Company
5th Jul 201912:07 pmRNSHolding(s) in Company
2nd Jul 20195:56 pmRNSHolding(s) in Company
2nd Jul 20195:56 pmRNSHolding(s) in Company
2nd Jul 20195:55 pmRNSHolding(s) in Company
1st Jul 20194:55 pmRNSHolding(s) in Company
28th Jun 20197:00 amRNSTotal Voting Rights
25th Jun 20194:57 pmRNSBlock Listing Application
17th Jun 20194:35 pmRNSPrice Monitoring Extension
7th Jun 20196:00 pmRNSHolding(s) in Company
7th Jun 20194:18 pmRNSResult of AGM
6th Jun 20196:23 pmRNSHolding(s) in Company
6th Jun 20194:11 pmRNSHolding(s) in Company
31st May 20197:00 amRNSTotal Voting Rights
28th May 20195:58 pmRNSHolding(s) in Company
28th May 20195:56 pmRNSHolding(s) in Company
21st May 20199:05 amRNSHolding(s) in Company
14th May 20194:24 pmRNSAnnual report and notice of AGM
8th May 20197:00 amRNSPublication of Tudorza Phase IV ASCENT in JAMA
3rd May 20192:18 pmRNSIssue of Equity
1st May 20197:00 amRNSFinal Results
30th Apr 20197:00 amRNSTotal Voting Rights
15th Apr 201911:55 amRNSHolding(s) in Company
1st Apr 20197:00 amRNSFDA approval of Duaklir for treatment of COPD
29th Mar 20194:40 pmRNSSecond Price Monitoring Extn
29th Mar 20194:35 pmRNSPrice Monitoring Extension
29th Mar 20193:58 pmRNSFDA website posts Duaklir NDA approval
29th Mar 20193:34 pmRNSCircassia announces FDA approval of Tudorza sNDA
29th Mar 20197:00 amRNSTotal Voting Rights
5th Mar 20194:53 pmRNSHolding(s) in Company
4th Mar 20194:04 pmRNSHolding(s) in Company
28th Feb 20197:00 amRNSTotal Voting Rights
11th Feb 20195:17 pmRNSHolding(s) in Company
8th Feb 20199:00 amRNSNotice of Results
6th Feb 20194:44 pmRNSHolding(s) in Company
6th Feb 20197:00 amRNSHolding(s) in Company
4th Feb 20195:57 pmRNSHolding(s) in Company
4th Feb 20198:06 amRNSSuccessful FDA Presubmission Meeting for AirNOvent
4th Feb 20198:06 amRNSAdmission to AIM
1st Feb 20194:36 pmRNSPrice Monitoring Extension
1st Feb 20194:03 pmRNSHolding(s) in Company
31st Jan 20197:00 amRNSTotal Voting Rights
30th Jan 20195:30 pmRNSCircassia Pharmaceuticals
30th Jan 20194:41 pmRNSSecond Price Monitoring Extn
30th Jan 20194:35 pmRNSPrice Monitoring Extension
28th Jan 20193:30 pmRNSHolding(s) in Company
28th Jan 20193:30 pmRNSHolding(s) in Company
25th Jan 201911:49 amRNSHolding(s) in Company
24th Jan 20197:00 amRNSCommercial rights acquired from AIT Therapeutics
18th Jan 20192:22 pmRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.